{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:22:47Z","timestamp":1790140967211,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment for adult patients with acute lymphoblastic leukemia (ALL). Cyclophosphamide plus total body irradiation (TBI\/Cy) or plus busulfan (Bu\/Cy) is a widely used pre-transplant conditioning regimen for ALL. We retrospectively compared the overall survival (OS), disease-free survival (DFS), and other transplant outcomes of allo-HSCT in 119 adult patients with ALL who received an HLA-matched sibling allo-HSCT using TBI-based versus non-TBI-based conditioning regimens. Patients were divided into two groups by their conditioning regimen: TBI\/Cy or Bu\/Cy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median OS was 11\u2009months in the TBI\/Cy group and 6.2\u2009months in the Bu\/Cy group. Median DFS was 11.1\u2009months in the TBI group versus 6.8\u2009months in the Bu group, without a statistically significant difference. A higher risk of relapse was observed with the Bu\/Cy regimen (HR 2.709, CI 95% 1.106 to 6.638,<jats:italic>p<\/jats:italic>= 0.029). Patients who received a transplant in \u2265 CR2 were associated with poor DFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the high relapse rate in the non-TBI regimen (Bu\/Cy), both regimens had no statistically significant differences in OS, DFS, and NRM. Additional prospective studies are indeed warranted to evaluate the long-term outcomes of radiation-free regimens, including oral and intravenous busulfan, and compare these regimens with TBI-based ones.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s43046-020-00042-4","type":"journal-article","created":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T23:02:42Z","timestamp":1592175762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-8147","authenticated-orcid":false,"given":"Mona Mahrous","family":"Abdelaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Gawaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal M.","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Kabbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"issue":"16","key":"42_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"42_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.33590\/emjhematol\/10312198","volume":"4","author":"X Thomas","year":"2016","unstructured":"Thomas X, Le Jeune C. Current management of adult acute lymphoblastic Leukemia: Emerging insights and outstanding questions. EMJ Hematol. 2016;4(1):117\u201328.","journal-title":"EMJ Hematol"},{"issue":"2","key":"42_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbmt.2012.09.019","volume":"19","author":"J Tracey","year":"2013","unstructured":"Tracey J, Zhang MJ, Thiel E, Sobocinski KA, Eapen M. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2013 Feb 1;19(2):255\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"42_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/ajh.23109","volume":"87","author":"T Mori","year":"2012","unstructured":"Mori T, Aisa Y, Kato J, Yamane A, Nakazato T, Shigematsu N, et al. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Am J Hematol. 2012 Apr;87(4):349\u201353.","journal-title":"Am J Hematol."},{"issue":"11","key":"42_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","volume":"22","author":"J Palmer","year":"2016","unstructured":"Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, et al. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and MarrowTtransplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22(11):1915\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"42_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12015-015-9625-5","volume":"12","author":"MZ Ratajczak","year":"2016","unstructured":"Ratajczak MZ, Suszynska M. Emerging strategies to enhance homing and engraftment of hematopoietic stem cells. Stem Cell Rev Rep. 2016;12(1):121\u20138.","journal-title":"Stem Cell Rev Rep."},{"issue":"2","key":"42_CR7","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.bbmt.2014.11.147","volume":"21","author":"RK Goyal","year":"2015","unstructured":"Goyal RK, Voller D, Goyal M, Sankaranarayan K. Grading acute GVHD: getting it right every time! Biol Blood Marrow Transplant. 2015;21(2):S118.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"42_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30\u20137.","journal-title":"Blood."},{"issue":"7","key":"42_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906\u201312.","journal-title":"Bone Marrow Transplant."},{"key":"42_CR10","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009 May 28;4(03)."},{"key":"42_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/OTT.S78567","volume":"8","author":"R Chen","year":"2015","unstructured":"Chen R, Campbell JL, Chen B. Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. OncoTargets Therapy. 2015;8:405\u201312.","journal-title":"OncoTargets Therapy."},{"issue":"3","key":"42_CR12","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/j.bbmt.2018.12.774","volume":"25","author":"YH Wang","year":"2019","unstructured":"Wang YH, Ko BS, Liao XW, Yao M, Tang JL. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem-cell transplantation for acute lymphoblastic leukemia: single tertiary center experience in Taiwan. Biol Blood Marrow Transplant. 2019;25(3):S188.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"42_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","volume":"24","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):726\u201333.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"42_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(1):139\u201349.","journal-title":"Haematologica."},{"issue":"1","key":"42_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/10428190903419130","volume":"51","author":"X Shi-Xia","year":"2010","unstructured":"Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma. 2010;51(1):50\u201360.","journal-title":"Leuk Lymphoma."},{"issue":"12","key":"42_CR16","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.bbmt.2016.09.007","volume":"22","author":"K Mitsuhashi","year":"2016","unstructured":"Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, et al. Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22(12):2194\u2013200.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"42_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5144\/1658-3876.2011.17","volume":"4","author":"T Gupta","year":"2011","unstructured":"Gupta T, Kannan S, Dantkale V, Laskar S. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2011;4(1):17\u201329.","journal-title":"Hematol Oncol Stem Cell Ther."},{"issue":"11","key":"42_CR18","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3109\/10428194.2013.779691","volume":"54","author":"C Eroglu","year":"2013","unstructured":"Eroglu C, Pala C, Kaynar L, Yaray K, Aksozen MT, Bankir M, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54(11):2474\u20139.","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"42_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pmn.2014.05.005","volume":"16","author":"K Vasquenza","year":"2015","unstructured":"Vasquenza K, Ruble K, Chen A, Billett C, Kozlowski L, Atwater S, Kost-Byerly S. Pain management for children during bone marrow and stem cell transplantation. Pain Manag Nurs. 2015;16(3):156\u201362.","journal-title":"Pain Manag Nurs."},{"issue":"11","key":"42_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.V104.11.349.349","volume":"104","author":"KA Sobocinski","year":"2004","unstructured":"Sobocinski KA, Thall PF, Bekele BN, Klein JP, Lennon S, Horowitz MM, et al. Matched pairs analysis of IV vs PO busulfan as a conditioning agent prior to transplantation. ASH Annual Meeting abstract. Blood. 2004;104(11):349.","journal-title":"Blood"},{"issue":"10","key":"42_CR21","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00277-018-3383-9","volume":"97","author":"I Sakellari","year":"2018","unstructured":"Sakellari I, Gavriilaki E, Chatziioannou K, Papathanasiou M, Mallouri D, Batsis I, et al. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. Ann Hematol. 2018;97(10):1987\u201394.","journal-title":"Ann Hematol."},{"issue":"11","key":"42_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/bmt.2010.314","volume":"46","author":"M Kalaycio","year":"2011","unstructured":"Kalaycio M, Bolwell B, Rybicki L, Absi A, Andresen S, Pohlman B, et al. BU-vs TBI-based conditioning for adult patients with ALL. Bone Marrow Transplant. 2011;46(11):1413\u20137.","journal-title":"Bone Marrow Transplant."},{"key":"42_CR23","unstructured":"D\u2019Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. Center for International Blood & Marrow Transplant Research. https:\/\/www.cibmtr.Org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx Updated June. 2018 Jun; 13."}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-020-00042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-020-00042-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-020-00042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:14:18Z","timestamp":1696241658000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-020-00042-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1186\/s43046-020-00042-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted by the stipulations of the local ethical and scientific committee of Tanta University, Egypt. Ethics approval code number 31611. The files were retrieved after concealing the personal details of patients to keep the confidentiality of data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}